Loh R K, Jabara H H, Geha R S
Department of Pediatrics, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
J Exp Med. 1994 Aug 1;180(2):663-71. doi: 10.1084/jem.180.2.663.
IgE synthesis requires interleukin 4 (IL-4) and a T-B cell interaction that involves the B cell antigen CD40 and its ligand expressed on activated T cells. IL-4 induces epsilon germline transcription whereas ligation of CD40 results in deletional S mu-->S epsilon switch recombination, expression of mature epsilon transcripts, and IgE synthesis and secretion. We demonstrate that disodium cromoglycate (DSCG), a drug commonly used for the prophylactic treatment of allergic disease, inhibits T cell-driven IgE synthesis by human B cells at concentrations readily achievable in the course of inhaled therapy for asthma. Inhibition of IgE synthesis by DSCG was not the result of drug toxicity because DSCG did not affect the viability of T and B cells or their proliferation to mitogens. DSCG did not interfere with CD40 ligand expression by T cells but clearly targeted the B cells because it inhibited IgE synthesis induced by anti-CD40 and IL-4 in populations of highly purified B cells. DSCG had no effect on the induction of epsilon germline transcripts by IL-4 but strongly inhibited CD40 mediated S mu-->S epsilon deletional switch recombination in IL-4-treated B cells as assayed by nested primer PCR. The effect of DSCG was not specific for CD40-mediated induction of IgE isotype switching because DSCG inhibited IgE synthesis as well as S mu-->S epsilon deletional switch recombination induced by hydrocortisone and IL-4 in B cells. Moreover, the effect of DSCG was not specific for IgE isotype switching because DSCG inhibited the synthesis of IgG4 by B cells sorted for lack of surface expression of IgG4 and stimulated with anti-CD40 and IL-4. DSCG caused only minimal inhibition (< 15%) of spontaneous IgE synthesis by lymphocytes from patients with the hyper-IgE syndrome and did not affect pokeweed mitogen-induced IgG and IgA synthesis by lymphocytes suggesting that it has little effect on B cells that have already undergone isotype switching. These results indicate that DSCG inhibits switching to IgE in B cells and suggest a novel potential mechanism for the prevention of allergic disease by DSCG.
IgE的合成需要白细胞介素4(IL-4)以及T细胞与B细胞的相互作用,这种相互作用涉及B细胞抗原CD40及其在活化T细胞上表达的配体。IL-4诱导ε基因转录,而CD40的连接导致缺失性的Sμ→Sε转换重组、成熟ε转录本的表达以及IgE的合成与分泌。我们证明,色甘酸钠(DSCG),一种常用于过敏性疾病预防性治疗的药物,在哮喘吸入治疗过程中易于达到的浓度下,可抑制人B细胞由T细胞驱动的IgE合成。DSCG对IgE合成的抑制并非药物毒性所致,因为DSCG不影响T细胞和B细胞的活力或它们对有丝分裂原的增殖。DSCG不干扰T细胞表达CD40配体,但明显作用于B细胞,因为它抑制了高度纯化的B细胞群体中由抗CD40和IL-4诱导的IgE合成。DSCG对IL-4诱导的ε基因转录没有影响,但通过巢式引物PCR检测发现,它强烈抑制了IL-4处理的B细胞中CD40介导的Sμ→Sε缺失性转换重组。DSCG的作用并非特异性针对CD40介导的IgE同种型转换诱导,因为DSCG也抑制了B细胞中由氢化可的松和IL-4诱导的IgE合成以及Sμ→Sε缺失性转换重组。此外,DSCG的作用并非特异性针对IgE同种型转换,因为DSCG抑制了分选的缺乏IgG4表面表达且用抗CD40和IL-4刺激的B细胞合成IgG4。DSCG对高IgE综合征患者淋巴细胞的自发性IgE合成仅产生最小程度的抑制(<15%),并且不影响商陆有丝分裂原诱导的淋巴细胞合成IgG和IgA,这表明它对已经经历同种型转换的B细胞影响很小。这些结果表明DSCG抑制B细胞向IgE的转换,并提示了DSCG预防过敏性疾病的一种新的潜在机制。